
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx Inc. reported a significant year-over-year revenue increase of 18%, reaching $483 million, while providing guidance for peak sales exceeding $1 billion, with projected revenue of $1 billion in 2029. The company's growth strategy includes expanding the depth and breadth of prescribing for its products, particularly through ongoing clinical trials such as the Phase 3 trial for IBSRELA, which could enhance revenue potential. Additionally, XPHOZAH demonstrated strong performance with a 41% increase in ex-Medicare business in 2025 and a 9% overall year-over-year growth in dispenses, further supported by investments in patient assistance programs and targeted prescriber engagement.
Bears say
Ardelyx Inc. faces significant financial challenges, as evidenced by their projected 1Q26 revenue for Ibsrela, which anticipates an 18% quarter-over-quarter decline despite an expected annual total of $422 million. The company's peak sales guidance of over $1 billion appears unachievable, compounded by concerns over reimbursement pricing structures and the risk of not acquiring essential product labeling features that could enhance market traction. Furthermore, the reported net loss of $0.4 million for 4Q25 and low patient adherence rates to phosphate binder treatment underscore potential difficulties in sustaining growth and securing necessary capital for ongoing operations.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares